Back to Search
Start Over
Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
- Source :
-
Multiple Sclerosis Journal . Nov2021, Vol. 27 Issue 13, p2116-2118. 3p. - Publication Year :
- 2021
-
Abstract
- Dengue fever (DF) is an endemic infectious disease in tropical and subtropical regions. Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen on B cells, which is approved for the treatment of both relapsing-remitting multiple sclerosis (RRMS) and primary-progressive multiple sclerosis (PPMS). We describe the favorable clinical outcome of DF in an RRMS patient treated with Ocrelizumab, who neither presented hemorrhagic or systemic shock symptoms nor reported neurological worsening. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 13524585
- Volume :
- 27
- Issue :
- 13
- Database :
- Academic Search Index
- Journal :
- Multiple Sclerosis Journal
- Publication Type :
- Academic Journal
- Accession number :
- 153370424
- Full Text :
- https://doi.org/10.1177/13524585211030214